Hydroxocobalamin

Drug Profile

Hydroxocobalamin

Alternative Names: AST-726

Latest Information Update: 25 Apr 2014

Price : $50

At a glance

  • Originator Ariston Pharmaceuticals
  • Developer TG Therapeutics Inc
  • Class Corrinoids; Vitamin B12 analogues; Vitamins
  • Mechanism of Action Vitamin B12 receptor protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Migraine; Vitamin deficiency

Most Recent Events

  • 07 Mar 2014 Discontinued - Phase-I for Vitamin deficiency in USA (Intranasal)
  • 07 Mar 2014 Discontinued - Phase-II for Migraine in European Union (Intranasal)
  • 08 Nov 2010 Manhattan Pharmaceuticals receives a Qualifying Therapeutic Discovery Project grant from the US Government for AST 726 development in Vitamin deficiency
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top